img

Global Cancer Pain Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Pain Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Cancer Pain market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Opioids accounting for % of the Cancer Pain global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Radiotherapy segment is altered to an % CAGR throughout this forecast period.
The global key companies of Cancer Pain include BioDelivery Science, ProStrakan Group, Teva pharmaceuticals, Eli-Lilly, Grunenthal Group, GW Pharmaceuticals, Johnson&Johnson, Meda Pharmaceuticals and Orexo, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Cancer Pain market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Cancer Pain landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Cancer Pain market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Cancer Pain market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Cancer Pain market. Readers of the report can become informed about current and future trends of the global Cancer Pain market and how they will impact market growth during the forecast period.



By Company


BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson&Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others

Segment by Application


Radiotherapy
Chemotherapy
Hormone Therapy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Cancer Pain in global and regional level.
Chapter 3Detailed analysis of Cancer Pain companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Pain revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Pain Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Opioids
1.2.3 Non-Steroidal Anti-Inflammatory Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Cancer Pain Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Radiotherapy
1.3.3 Chemotherapy
1.3.4 Hormone Therapy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Cancer Pain Market Size (2018-2034)
2.2 Cancer Pain Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Cancer Pain Market Size by Region (2018-2024)
2.4 Global Cancer Pain Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Cancer Pain Countries Ranking by Market Size
3 Cancer Pain Competitive by Company
3.1 Global Cancer Pain Revenue by Players
3.1.1 Global Cancer Pain Revenue by Players (2018-2024)
3.1.2 Global Cancer Pain Market Share by Players (2018-2024)
3.2 Global Cancer Pain Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Cancer Pain Revenue
3.4 Global Cancer Pain Market Concentration Ratio
3.4.1 Global Cancer Pain Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Pain Revenue in 2022
3.5 Global Key Players of Cancer Pain Head office and Area Served
3.6 Global Key Players of Cancer Pain, Product and Application
3.7 Global Key Players of Cancer Pain, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Cancer Pain Breakdown Data by Type
4.1 Global Cancer Pain Historic Revenue by Type (2018-2024)
4.2 Global Cancer Pain Forecasted Revenue by Type (2024-2034)
5 Global Cancer Pain Breakdown Data by Application
5.1 Global Cancer Pain Historic Market Size by Application (2018-2024)
5.2 Global Cancer Pain Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Cancer Pain Revenue by Company (2021-2024)
6.2 North America Cancer Pain Revenue by Type (2018-2034)
6.3 North America Cancer Pain Revenue by Application (2018-2034)
6.4 North America Cancer Pain Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Cancer Pain Revenue by Company (2021-2024)
7.2 Europe Cancer Pain Revenue by Type (2018-2034)
7.3 Europe Cancer Pain Revenue by Application (2018-2034)
7.4 Europe Cancer Pain Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Cancer Pain Revenue by Company (2021-2024)
8.2 Asia Pacific Cancer Pain Revenue by Type (2018-2034)
8.3 Asia Pacific Cancer Pain Revenue by Application (2018-2034)
8.4 Asia Pacific Cancer Pain Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Cancer Pain Revenue by Company (2021-2024)
9.2 Latin America Cancer Pain Revenue by Type (2018-2034)
9.3 Latin America Cancer Pain Revenue by Application (2018-2034)
9.4 Latin America Cancer Pain Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Cancer Pain Revenue by Company (2021-2024)
10.2 Middle East and Africa Cancer Pain Revenue by Type (2018-2034)
10.3 Middle East and Africa Cancer Pain Revenue by Application (2018-2034)
10.4 Middle East and Africa Cancer Pain Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 BioDelivery Science
11.1.1 BioDelivery Science Company Details
11.1.2 BioDelivery Science Business Overview
11.1.3 BioDelivery Science Cancer Pain Products and Services
11.1.4 BioDelivery Science Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.1.5 BioDelivery Science Cancer Pain SWOT Analysis
11.1.6 BioDelivery Science Recent Development
11.2 ProStrakan Group
11.2.1 ProStrakan Group Company Details
11.2.2 ProStrakan Group Business Overview
11.2.3 ProStrakan Group Cancer Pain Products and Services
11.2.4 ProStrakan Group Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.2.5 ProStrakan Group Cancer Pain SWOT Analysis
11.2.6 ProStrakan Group Recent Development
11.3 Teva pharmaceuticals
11.3.1 Teva pharmaceuticals Company Details
11.3.2 Teva pharmaceuticals Business Overview
11.3.3 Teva pharmaceuticals Cancer Pain Products and Services
11.3.4 Teva pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.3.5 Teva pharmaceuticals Cancer Pain SWOT Analysis
11.3.6 Teva pharmaceuticals Recent Development
11.4 Eli-Lilly
11.4.1 Eli-Lilly Company Details
11.4.2 Eli-Lilly Business Overview
11.4.3 Eli-Lilly Cancer Pain Products and Services
11.4.4 Eli-Lilly Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.4.5 Eli-Lilly Cancer Pain SWOT Analysis
11.4.6 Eli-Lilly Recent Development
11.5 Grunenthal Group
11.5.1 Grunenthal Group Company Details
11.5.2 Grunenthal Group Business Overview
11.5.3 Grunenthal Group Cancer Pain Products and Services
11.5.4 Grunenthal Group Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.5.5 Grunenthal Group Cancer Pain SWOT Analysis
11.5.6 Grunenthal Group Recent Development
11.6 GW Pharmaceuticals
11.6.1 GW Pharmaceuticals Company Details
11.6.2 GW Pharmaceuticals Business Overview
11.6.3 GW Pharmaceuticals Cancer Pain Products and Services
11.6.4 GW Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.6.5 GW Pharmaceuticals Cancer Pain SWOT Analysis
11.6.6 GW Pharmaceuticals Recent Development
11.7 Johnson&Johnson
11.7.1 Johnson&Johnson Company Details
11.7.2 Johnson&Johnson Business Overview
11.7.3 Johnson&Johnson Cancer Pain Products and Services
11.7.4 Johnson&Johnson Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.7.5 Johnson&Johnson Cancer Pain SWOT Analysis
11.7.6 Johnson&Johnson Recent Development
11.8 Meda Pharmaceuticals
11.8.1 Meda Pharmaceuticals Company Details
11.8.2 Meda Pharmaceuticals Business Overview
11.8.3 Meda Pharmaceuticals Cancer Pain Products and Services
11.8.4 Meda Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.8.5 Meda Pharmaceuticals Cancer Pain SWOT Analysis
11.8.6 Meda Pharmaceuticals Recent Development
11.9 Orexo
11.9.1 Orexo Company Details
11.9.2 Orexo Business Overview
11.9.3 Orexo Cancer Pain Products and Services
11.9.4 Orexo Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.9.5 Orexo Cancer Pain SWOT Analysis
11.9.6 Orexo Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Cancer Pain Products and Services
11.10.4 Sanofi Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.10.5 Sanofi Cancer Pain SWOT Analysis
11.10.6 Sanofi Recent Development
11.11 WEX Pharmaceuticals
11.11.1 WEX Pharmaceuticals Company Details
11.11.2 WEX Pharmaceuticals Business Overview
11.11.3 WEX Pharmaceuticals Cancer Pain Products and Services
11.11.4 WEX Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024)
11.11.5 WEX Pharmaceuticals Recent Development
12 Cancer Pain Market Dynamics
12.1 Cancer Pain Industry Trends
12.2 Cancer Pain Market Drivers
12.3 Cancer Pain Market Challenges
12.4 Cancer Pain Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Cancer Pain Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Opioids
Table 3. Key Players of Non-Steroidal Anti-Inflammatory Drugs
Table 4. Key Players of Others
Table 5. Global Cancer Pain Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Cancer Pain Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 7. Global Cancer Pain Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Cancer Pain Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global Cancer Pain Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 10. Global Cancer Pain Revenue by Players (2018-2024) & (US$ Million)
Table 11. Global Cancer Pain Market Share by Players (2018-2024)
Table 12. Global Top Cancer Pain Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Pain as of 2022)
Table 13. Ranking of Global Top Cancer Pain Companies by Revenue (US$ Million) in 2022
Table 14. Global 5 Largest Players Market Share by Cancer Pain Revenue (CR5 and HHI) & (2018-2024)
Table 15. Global Key Players of Cancer Pain, Headquarters and Area Served
Table 16. Global Key Players of Cancer Pain, Product and Application
Table 17. Global Key Players of Cancer Pain, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Cancer Pain Market Size by Type (2018-2024) & (US$ Million)
Table 20. Global Cancer Pain Revenue Market Share by Type (2018-2024)
Table 21. Global Cancer Pain Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global Cancer Pain Revenue Market Share by Type (2024-2034)
Table 23. Global Cancer Pain Market Size by Application (2018-2024) & (US$ Million)
Table 24. Global Cancer Pain Revenue Market Share by Application (2018-2024)
Table 25. Global Cancer Pain Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global Cancer Pain Revenue Market Share by Application (2024-2034)
Table 27. North America Cancer Pain Revenue by Company (2021-2024) & (US$ Million)
Table 28. North America Cancer Pain Revenue by Type (2018-2024) & (US$ Million)
Table 29. North America Cancer Pain Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America Cancer Pain Revenue by Application (2018-2024) & (US$ Million)
Table 31. North America Cancer Pain Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America Cancer Pain Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 33. North America Cancer Pain Revenue by Country (2018-2024) & (US$ Million)
Table 34. North America Cancer Pain Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe Cancer Pain Revenue by Company (2021-2024) & (US$ Million)
Table 36. Europe Cancer Pain Revenue by Type (2018-2024) & (US$ Million)
Table 37. Europe Cancer Pain Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe Cancer Pain Revenue by Application (2018-2024) & (US$ Million)
Table 39. Europe Cancer Pain Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe Cancer Pain Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Europe Cancer Pain Revenue by Country (2018-2024) & (US$ Million)
Table 42. Europe Cancer Pain Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific Cancer Pain Revenue by Company (2021-2024) & (US$ Million)
Table 44. Asia Pacific Cancer Pain Revenue by Type (2018-2024) & (US$ Million)
Table 45. Asia Pacific Cancer Pain Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific Cancer Pain Revenue by Application (2018-2024) & (US$ Million)
Table 47. Asia Pacific Cancer Pain Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific Cancer Pain Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 49. Asia Pacific Cancer Pain Revenue by Region (2018-2024) & (US$ Million)
Table 50. Asia Pacific Cancer Pain Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America Cancer Pain Revenue by Company (2021-2024) & (US$ Million)
Table 52. Latin America Cancer Pain Revenue by Type (2018-2024) & (US$ Million)
Table 53. Latin America Cancer Pain Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America Cancer Pain Revenue by Application (2018-2024) & (US$ Million)
Table 55. Latin America Cancer Pain Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America Cancer Pain Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 57. Latin America Cancer Pain Revenue by Country (2018-2024) & (US$ Million)
Table 58. Latin America Cancer Pain Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa Cancer Pain Revenue by Company (2021-2024) & (US$ Million)
Table 60. Middle East and Africa Cancer Pain Revenue by Type (2018-2024) & (US$ Million)
Table 61. Middle East and Africa Cancer Pain Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Cancer Pain Revenue by Application (2018-2024) & (US$ Million)
Table 63. Middle East and Africa Cancer Pain Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Cancer Pain Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 65. Middle East and Africa Cancer Pain Revenue by Country (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Cancer Pain Revenue by Country (2024-2034) & (US$ Million)
Table 67. BioDelivery Science Company Details
Table 68. BioDelivery Science Business Overview
Table 69. BioDelivery Science Cancer Pain Product and Services
Table 70. BioDelivery Science Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 71. BioDelivery Science Cancer Pain SWOT Analysis
Table 72. BioDelivery Science Recent Development
Table 73. ProStrakan Group Company Details
Table 74. ProStrakan Group Business Overview
Table 75. ProStrakan Group Cancer Pain Product and Services
Table 76. ProStrakan Group Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 77. ProStrakan Group Cancer Pain SWOT Analysis
Table 78. ProStrakan Group Recent Development
Table 79. Teva pharmaceuticals Company Details
Table 80. Teva pharmaceuticals Business Overview
Table 81. Teva pharmaceuticals Cancer Pain Product and Services
Table 82. Teva pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 83. Teva pharmaceuticals Cancer Pain SWOT Analysis
Table 84. Teva pharmaceuticals Recent Development
Table 85. Eli-Lilly Company Details
Table 86. Eli-Lilly Business Overview
Table 87. Eli-Lilly Cancer Pain Product and Services
Table 88. Eli-Lilly Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 89. Eli-Lilly Cancer Pain SWOT Analysis
Table 90. Eli-Lilly Recent Development
Table 91. Grunenthal Group Company Details
Table 92. Grunenthal Group Business Overview
Table 93. Grunenthal Group Cancer Pain Product and Services
Table 94. Grunenthal Group Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 95. Grunenthal Group Cancer Pain SWOT Analysis
Table 96. Grunenthal Group Recent Development
Table 97. GW Pharmaceuticals Company Details
Table 98. GW Pharmaceuticals Business Overview
Table 99. GW Pharmaceuticals Cancer Pain Product and Services
Table 100. GW Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 101. GW Pharmaceuticals Cancer Pain SWOT Analysis
Table 102. GW Pharmaceuticals Recent Development
Table 103. Johnson&Johnson Company Details
Table 104. Johnson&Johnson Business Overview
Table 105. Johnson&Johnson Cancer Pain Product and Services
Table 106. Johnson&Johnson Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 107. Johnson&Johnson Cancer Pain SWOT Analysis
Table 108. Johnson&Johnson Recent Development
Table 109. Meda Pharmaceuticals Company Details
Table 110. Meda Pharmaceuticals Business Overview
Table 111. Meda Pharmaceuticals Cancer Pain Product and Services
Table 112. Meda Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 113. Meda Pharmaceuticals Cancer Pain SWOT Analysis
Table 114. Meda Pharmaceuticals Recent Development
Table 115. Orexo Company Details
Table 116. Orexo Business Overview
Table 117. Orexo Cancer Pain Product and Services
Table 118. Orexo Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 119. Orexo Cancer Pain SWOT Analysis
Table 120. Orexo Recent Development
Table 121. Sanofi Company Details
Table 122. Sanofi Business Overview
Table 123. Sanofi Cancer Pain Product and Services
Table 124. Sanofi Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 125. Sanofi Cancer Pain SWOT Analysis
Table 126. Sanofi Recent Development
Table 127. WEX Pharmaceuticals Company Details
Table 128. WEX Pharmaceuticals Business Overview
Table 129. WEX Pharmaceuticals Cancer Pain Product and Services
Table 130. WEX Pharmaceuticals Cancer Pain Revenue in Cancer Pain Business (2018-2024) & (US$ Million)
Table 131. WEX Pharmaceuticals Recent Development
Table 132. Cancer Pain Market Trends
Table 133. Cancer Pain Market Drivers
Table 134. Cancer Pain Market Challenges
Table 135. Cancer Pain Market Restraints
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Pain Product Picture
Figure 2. Global Cancer Pain Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Cancer Pain Market Share by Type: 2022 VS 2034
Figure 4. Opioids Features
Figure 5. Non-Steroidal Anti-Inflammatory Drugs Features
Figure 6. Others Features
Figure 7. Global Cancer Pain Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 8. Global Cancer Pain Market Share by Application: 2022 VS 2034
Figure 9. Radiotherapy
Figure 10. Chemotherapy
Figure 11. Hormone Therapy
Figure 12. Others
Figure 13. Cancer Pain Report Years Considered
Figure 14. Global Cancer Pain Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Cancer Pain Market Size 2018-2034 (US$ Million)
Figure 16. Global Cancer Pain Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Cancer Pain Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Cancer Pain Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Cancer Pain Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Cancer Pain Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Cancer Pain Market Share by Players in 2022
Figure 22. Global Top Cancer Pain Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Pain as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Cancer Pain Revenue in 2022
Figure 24. North America Cancer Pain Revenue Market Share by Company in 2022
Figure 25. North America Cancer Pain Revenue Market Share by Type (2018-2034)
Figure 26. North America Cancer Pain Revenue Market Share by Application (2018-2034)
Figure 27. North America Cancer Pain Revenue Share by Country (2018-2034)
Figure 28. U.S. Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Cancer Pain Revenue Market Share by Company in 2022
Figure 31. Europe Cancer Pain Revenue Market Share by Type (2018-2034)
Figure 32. Europe Cancer Pain Revenue Market Share by Application (2018-2034)
Figure 33. Europe Cancer Pain Revenue Share by Country (2018-2034)
Figure 34. Germany Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 35. France Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 36. U.K. Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Cancer Pain Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Cancer Pain Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Cancer Pain Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Cancer Pain Revenue Share by Region (2018-2034)
Figure 43. China Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 46. India Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 48. Taiwan Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 52. Philippines Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 53. Vietnam Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 54. Latin America Cancer Pain Revenue Market Share by Company in 2022
Figure 55. Latin America Cancer Pain Revenue Market Share by Type (2018-2034)
Figure 56. Latin America Cancer Pain Revenue Market Share by Application (2018-2034)
Figure 57. Latin America Cancer Pain Revenue Share by Country (2018-2034)
Figure 58. Mexico Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 59. Brazil Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 60. Argentina Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 61. Middle East and Africa Cancer Pain Revenue Market Share by Company in 2022
Figure 62. Middle East and Africa Cancer Pain Revenue Market Share by Type (2018-2034)
Figure 63. Middle East and Africa Cancer Pain Revenue Market Share by Application (2018-2034)
Figure 64. Middle East and Africa Cancer Pain Revenue Share by Country (2018-2034)
Figure 65. Turkey Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 66. Saudi Arabia Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 67. U.A.E Cancer Pain Revenue (2018-2034) & (US$ Million)
Figure 68. BioDelivery Science Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 69. ProStrakan Group Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 70. Teva pharmaceuticals Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 71. Eli-Lilly Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 72. Grunenthal Group Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 73. GW Pharmaceuticals Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 74. Johnson&Johnson Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 75. Meda Pharmaceuticals Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 76. Orexo Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 77. Sanofi Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 78. WEX Pharmaceuticals Revenue Growth Rate in Cancer Pain Business (2018-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed